Supernus Pharmaceuticals
SUPN
#4182
Rank
A$3.94 B
Marketcap
A$68.77
Share price
1.29%
Change (1 day)
19.92%
Change (1 year)

Supernus Pharmaceuticals (SUPN) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : A$0.55 Billion

According to Supernus Pharmaceuticals 's latest financial reports the company's total liabilities are A$0.55 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Supernus Pharmaceuticals - Total liabilities on balance sheet (from 2009 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31A$0.53 B2.21%
2023-12-31A$0.52 B-56.42%
2022-12-31A$1.19 B-0.42%
2021-12-31A$1.20 B22%
2020-12-31A$0.98 B22.39%
2019-12-31A$0.80 B8.3%
2018-12-31A$0.74 B270.47%
2017-12-31A$0.20 B23.03%
2016-12-31A$0.16 B18.33%
2015-12-31A$0.13 B17.64%
2014-12-31A$0.11 B35.07%
2013-12-31A$86.92 M148.02%
2012-12-31A$35.04 M-18.86%
2011-12-31A$43.19 M-51.96%
2010-12-31A$89.91 M-6.14%
2009-12-31A$95.79 M-19.43%
2008-12-31A$0.11 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
United Therapeutics
UTHR
A$1.14 B 105.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$137.12 B 24,511.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$117.86 B 21,054.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
A$49.55 B 8,794.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
A$170.93 B 30,579.00%๐Ÿ‡บ๐Ÿ‡ธ USA